We are live on ! Find out more
CSTL icon

Castle Biosciences
CSTL

153 hedge funds and large institutions have $514M invested in Castle Biosciences in 2022 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 51 increasing their positions, 55 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

518% more call options, than puts

Call options by funds: $946K | Put options by funds: $153K

1.05% more ownership

Funds ownership: 83.11% → 84.15% (+1%)

7% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 55

3% less funds holding

Funds holding: 157 → 153 (-4)

10% less capital invested

Capital invested by funds: $569M → $514M (-$54.2M)

12% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 26

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
153
Holders Change
-4
Holders Change %
-2.55%
% of All Funds
2.46%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
23
Increased
51
Reduced
55
Closed
26
Calls
$946K
Puts
$153K
Net Calls
+$793K
Net Calls Change
-$5.04M

Top Buyers

Rank Fund Capital Flow
1
Principal Financial Group
Principal Financial Group
Iowa
+$11M
2
PCM
Portolan Capital Management
Massachusetts
+$6.56M
3
GIM
Granahan Investment Management
Massachusetts
+$6.54M
4
DM
Deerfield Management
New York
+$6.31M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.67M

Top Sellers

Rank Fund Capital Flow
1
SCM
Soleus Capital Management
Connecticut
-$7.77M
2
Invesco
Invesco
Georgia
-$7.58M
3
SBH
Segall Bryant & Hamill
Illinois
-$5.28M
4
Citadel Advisors
Citadel Advisors
Florida
-$4.2M
5
Morgan Stanley
Morgan Stanley
New York
-$3.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
Point72 Asset Management
26
Point72 Asset Management
Connecticut
$4.74M +$4.67M +201,381 New
Charles Schwab
27
Charles Schwab
California
$4.34M +$160K +6,910 +4%
SCM
28
Stonepine Capital Management
Oregon
$4.2M +$4.13M +178,240 New
MPAM
29
Monarch Partners Asset Management
Massachusetts
$4.01M -$427K -18,436 -10%
TFS
30
TrustCore Financial Services
Tennessee
$3.88M +$3.38K +146 +0.1%
FLAM
31
First Light Asset Management
Minnesota
$3.8M -$37.6K -1,620 -1%
UBS AM
32
UBS AM
Illinois
$3.74M +$295K +12,717 +9%
Two Sigma Advisers
33
Two Sigma Advisers
New York
$3.11M -$494K -21,300 -14%
Norges Bank
34
Norges Bank
Norway
$3.09M -$125K -5,400 -4%
Ameriprise
35
Ameriprise
Minnesota
$2.62M -$493K -21,281 -16%
PAMP
36
Polar Asset Management Partners
Ontario, Canada
$2.52M +$2.48M +107,100 New
VOYA Investment Management
37
VOYA Investment Management
Georgia
$2.46M +$918K +39,608 +61%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$1.95M +$45.5K +1,964 +2%
AG
39
Algert Global
California
$1.62M +$439K +18,920 +38%
Ohio Public Employees Retirement System (OPERS)
40
Ohio Public Employees Retirement System (OPERS)
Ohio
$1.57M -$280K -12,070 -15%
Tudor Investment Corp
41
Tudor Investment Corp
Connecticut
$1.39M +$1.04M +44,665 +314%
Morgan Stanley
42
Morgan Stanley
New York
$1.37M -$3.19M -137,484 -70%
IP
43
Isthmus Partners
Wisconsin
$1.36M +$27.2K +1,173 +2%
SSA
44
Schonfeld Strategic Advisors
New York
$1.35M -$2.53M -108,935 -65%
Two Sigma Investments
45
Two Sigma Investments
New York
$1.27M -$1.57M -67,603 -56%
Swiss National Bank
46
Swiss National Bank
Switzerland
$1.27M +$23.2K +1,000 +2%
SI
47
Stephens Inc
Arkansas
$1.26M +$205K +8,857 +20%
Bank of America
48
Bank of America
North Carolina
$1.15M -$1.76M -76,117 -61%
ZIM
49
Zacks Investment Management
Illinois
$1M +$985K +42,489 New
EGM
50
Engineers Gate Manager
New York
$931K +$695K +29,992 +314%
1
2
3 4 5

CSTL Hedge Fund Activity: Q4 2022 in Review

153 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q4 2022, worth a combined $514M — down 9.5% from $569M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of CSTL and 23 opened new positions — a net loss of 3 holders — while 55 trimmed existing stakes and 51 added.

The largest buyer was Principal Financial Group, adding an estimated $11M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $7.77M sold.

  • 153 institutional investors held Castle Biosciences (CSTL) as of Q4 2022, down from 157 in Q3 2022.
  • Funds reported $514M of Castle Biosciences stock for Q4 2022, down 9.5% quarter-over-quarter.
  • 23 funds opened new Castle Biosciences positions in Q4 2022 and 26 closed out, a net change of -3 holders.
  • The largest Castle Biosciences buyer in Q4 2022 was Principal Financial Group, an estimated $11M added.
  • The largest Castle Biosciences seller in Q4 2022 was Soleus Capital Management, an estimated $7.77M sold.

Based on aggregated 13F filings for Q4 2022.